Markets:

Overview

News

Currencies

International

Treasuries

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

3.650 +0.030 (+0.83%)

Streaming Delayed Price Updated: 3:31 PM EDT, Jul 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 31, 2022

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

SAB Biotherapeutics Shifts Focus On Infection Candidate As DoD Contract Closes ↗

August 10, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 06, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 18, 2022

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...

Via Benzinga

Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday ↗

June 27, 2022

Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 05, 2022

Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 141.5% to $5.46 during Tuesday's regular session. Trading volume for this security as of 13:30 EST is 114.7...

Via Benzinga

51 Biggest Movers From Yesterday ↗

April 06, 2022

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are...

Via Benzinga

30 Stocks Moving In Tuesday's Mid-Day Session ↗

April 05, 2022

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 139% to $5.40 after the company announced that two of its designed mRNA molecules are effective at destroying...

Via Benzinga

53 Biggest Movers From Yesterday ↗

April 01, 2022

Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 31, 2022

Gainers Longeveron (NASDAQ:LGVN) stock rose 60.6% to $10.79 during Thursday's regular session. As of 13:31 EST, this security is trading at a volume of 84.1 million...

Via Benzinga

36 Stocks Moving In Thursday's Mid-Day Session ↗

March 31, 2022

Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 71% to $11.57 after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 24, 2022

Gainers

Via Benzinga

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗

March 06, 2022

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...

Via Benzinga

Mid-Afternoon Market Update: Dow Gains 2%; SAB Biotherapeutics Shares Slide ↗

March 02, 2022

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 2% on Wednesday. The Dow traded up 2.07% to 33,983.50 while the NASDAQ rose 1.77% to 13,771.67. The...

Via Benzinga

68 Biggest Movers From Yesterday ↗

March 03, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 02, 2022

Gainers Trevi Therapeutics (NASDAQ:TRVI) shares rose 46.6% to $1.28 during Wednesday's regular session. As of 12:30 EST, Trevi Therapeutics's stock is trading at a...

Via Benzinga

41 Stocks Moving In Wednesday's Mid-Day Session ↗

March 02, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported...

Via Benzinga

Mid-Day Market Update: Nasdaq Surges 150 Points; US Crude Oil Inventories Fall By 2.6M Barrels ↗

March 02, 2022

U.S. stocks extended gains midway through trading, with the Nasdaq index jumping 150 points on Wednesday. The Dow traded up 1.71% to 33,865.43 while the NASDAQ rose 1.11% to 13,...

Via Benzinga

Mid-Morning Market Update: U.S. Stocks Mixed; Dollar Tree Reports Mixed Q4 Results ↗

March 02, 2022

U.S. stocks opened mixed this morning, with the Dow Jones adding more than 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.66% to 33,513.04...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 02, 2022

Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...

Via Benzinga

NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185 ↗

March 02, 2022

SAB Biotherapeutics Inc (NASDAQ: SABS) said that due to low hospitalization and death rates in the trial, the National Institutes of Health's (NIH) ACTIV-2 Program is...

Via Benzinga

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi ↗

March 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...

Via Benzinga

On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial ↗

January 24, 2022

SAB Biotherapeutics Inc (NASDAQ: SABS) has reported positive Phase 2 safety and efficacy data demonstrating that SAB-185 met the criteria required to move to Phase...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 24, 2022

Gainers SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 15.0% to $6.3 during Monday's pre-market session. The market value of their outstanding shares is at $...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 19, 2022

During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

January 14, 2022

During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to...

Via Benzinga

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗

December 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...

Via Benzinga

FDA Lab Testing Confirms SAB Biotherapeutics' COVID-19 Antibody Neutralizes Omicron Variant ↗

December 16, 2021

SAB Biotherapeutics Inc (NASDAQ: SABS) announced that SAB-185, its COVID-19 therapeutic candidate, retains neutralization activity against the omicron variant in an...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 16, 2021

Good morning, trader! We're getting right into the swing of things with a breakdown of the biggest pre-market stock movers for Thursday!

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.